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The prognostic value of lymph node status has
been partly reappraised since the initial directions of
Halsted’s theory on the need for radical control of
breast cancer at the loco-regional level and Fisher and
Helmann’s theories on reducing radical surgery to the
Consensus of St. Gallen on the role of other factors,
such as patient age, tumor diameter, presence of hor-
monal receptors, grading, tumoral growth, oncogenes.
Many studies (1-4) have underlined the scarce thera-
peutic importance of axillary lymphectomy other than
for staging, since it is burdened by a wide range of
complications and sequelae (20-73%) such as chronic
lymphedema, paresthesia, decreased mobility, psycho-
logical stress (5-7). 
One way devised to reduce the entity of these com-
plications (seroma, limb edema) and a less radical te-
chnique than of axillary dissection, was lymph node
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Background. Sentinel node (SN) has been proved to be a reliable
technique in predicting the lymphnodal state of the axilla in breast
cancer. For the majority of the authors the intradermal and peritumo-
ral injection is the best way.
Patients and Methods. Our experience, from 1997, includes 587
cases of SN in women with resectable breast cancer less than 3 cm of
diameter. We performed the lymphoscintigraphy after a peritumoral
injection of radioactive tracer and, if the lesion was superficial, we as-
sociated an intradermal injection on the skin above the lesion itself.
Two patients had plurifocal right breast cancer. We did two separate
injections around each tumor.
Results. The radioactive tracer spread towards the internal mam-
mary chain and omolateral axillary nodes.
Conclusions. We consider the peritumoral injection as essential in
tumors located deeply in the breast (under ultrasound guide if not pal-
pable) together with intradermal injection in superficial ones. Using
this technique the possibility of a misindentification of the SN is redu-
ced.
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Obiettivo. La biopsia del linfonodo sentinella rappresenta una ef-
ficace tecnica nella valutazione delle condizioni linfonodali ascellari
nel cancro della mammella. Secondo la letteratura sono più utili
l’iniezione intradermica e quella peritumorale.
Pazienti e metodi. La nostra esperienza, dal 1997 ad oggi, ri-
guarda 587 casi di biopsia del linfonodo sentinella in pazienti con tu-
more della mammella inferiore a 3 cm. Abbiamo eseguito una linfo-
scintigrafia dopo l’iniezione peritumorale e, se la lesione era superficia-
le, veniva associata un’iniezione intradermica sulla cute sovrastante la
lesione. In 2 pazienti il tumore era plurifocale a destra. Abbiamo pra-
ticato in questi casi due iniezioni separate.
Risultati. Il tracciante radioattivo si dirigeva verso la catena linfo-
nodale mammaria interna e verso quella ascellare omolaterale.
Conclusioni. Riteniamo l’iniezione peritumorale del tracciante
indispensabile in quei tumori localizzati profondamente nella mam-
mella (sotto guida ecografica se non palpabili) associando una iniezio-
ne intradermica in quelli superficiali. Con questa metodica si riduce
la possibilità di errore nella identificazione del linfonodo sentinella.
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sampling (8) but this method was found to produce a
high rate (24-42%) of false negatives, presumably be-
cause of incorrect mapping of lymphatic drainage or
the number of lymph nodes removed too small. Sub-
sequently, axillary lymphectomy is generally reserved
to levels 1 and 2 in T1 a-b (9-10), keeping in mind
that in T 1 the rate of axillary metastasis is < 12% (11-
12). 
Preoperative diagnostic imaging (ultrasonography,
TC, MR, scintimammography) (13, 14) has not im-
proved detection rates of axillary lymph node status
and lymphonodal echo-guided fine needle aspiration
cytology is burdened by elevated false negative rates
(40%). PET has shown a good diagnostic sensitivity
(90%) with a negative predictive value  of around 93%
(15, 16). 
Drawing on these considerations sentinel node
(SN) biopsy appears attractive; SN biopsy requires a
multidisciplinary approach (nuclear physician, sur-
geon, pathologist) and informed consensus from pa-
tients. The SN is detected using vital stain (detection
rate from 66% to 98%) (17) or with radioactive tracer
( detection rate from 82% to 98%) (18). Predictive va-
lue of SN biopsy is between 95% and 100% (19) with
false negative between 0% and 15% and the number
of SN between 1 and 7 (20). The greater part of the
authors consider the intradermal and/or peritumoral
injection as the best way (21) but recently the intrareo-
lar injection has been proposed. This theory is based
on the hypothesis that the mammary gland and its
skin constitute an anatomo-functional unit whose fir-
st lymphonodal drainage (SN) is situated in the lower
part of the axilla. 
Our experience, from December 1997 to Decem-
ber 2007, includes 587 cases of SN biopsy in women
with respectable breast cancer less than 3 cm of diame-
ter. We performed the lymphoscintigraphy after a pe-
ritumoral injection of radioactive tracer and, if the le-
sion was superficial, we associated an intradermal
injection on the skin above the lesion itself; if the tu-
mor was small, not palpable or situated deep in the
breast, we did the injection under ultrasound guide.
Using this technique we have correctly identified the
SN with the lymphoscintigraphy in 97,7% of cases
with 5,8% of false negative.
Patients and methods
Case n. 1
A 57 years old woman with a plurifocal right breast cancer:
one lesion (1,3 cm) was situated under the areola and the other
one (2 cm) in the middle of inferior quadrants. According to the
mammography both lesions appeared as infiltrating: cytology was
positive for malignant cells in both. In order to verify whether the
two lesions drained to a single SN, we did two separate injections,
in different hours, around each tumor. We used 10 to 40 nm hu-
man albumin particles (Nanocoll) marked with 20-40 MBq for a
total amount always less than 1 ml. We started injecting on the
medial edges of the inferior quadrants tumor. Scintigraphic images
were taken contextually to the injection. The patient was placed in
supine position with the arm in the same position as during the
operation. The peak of emission of Tc99m was used to acquire the
images, which clearly showed how the tracer quickly and exclusi-
vely spread from the centre of the injection medially towards two
nodes of the internal mammary chain. After waiting 15 minutes,
in order to show eventual late disseminations to other nodes, we
injected a second dose around the retroareolar tumor: the tracer
headed to an omolateral axillary node. During the operation we
correctly identified the SN of the axilla. We did not remove the in-
ternal mammary chain lymphonode, as we feel that such a route is
only an indication to adjuvant radiotheraphy of the region.
Case n. 2
A 43 years old woman suffered from a plurifocal right breast
cancer: one lesion (1,2 cm) was situated in the internal inferior
quadrant and the other one (1 cm) in the upper external quadrant.
Mammography and cytology were positive for malignant cells in
both lesions. Scintigraphic images with the same technique of the
first case showed a spread towards one node of the internal mam-
mary chain and one node of omolateral axillary chain. During the
operation we correctly identified the SN of the axilla and did not
remove the internal mammary chain.
Discussion
Radiotracer injection may be problematic because
of differences in formulation. Some authors prefer in-
tradermal or peritumoral injection or both, while
others (22) showed higher detection rates (65%) of the
SN in the internal mammary chain of lymph nodes
with deep retrotumoral injection in tumors spreading
to the medial quadrants. Some authors (23) who con-
sider a single lymphatic drainage for all quadrants of
the breast reported their preference for retroareolar
injection. Other authors (24) prefer periareolar injec-
tion, especially in nonpalpable lesions or of the upper
external quadrant in order to reduce high residual
background during intraoperative detection with pro-
be. Yet other authors prefer intratumoral injection
(25). 
About the role of the SN in the internal mammary
chain some studies (26) have reported very low rates of
metastatic SN (8-16,7%) which, considering other
factors conditioning adjuvant chemotherapy, probably
do not justify surgical ablation of the SN of the inter-
nal mammary lymph chain.
Conclusions
Even though rare (27), this experience leaded us to
the conviction that the identification of the SN cannot
be simplified with the subareolar injection. With this
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technique the identification of a SN is in fact possible
but, in our experience, the node found does not neces-
sarily drain the tumor area, We consider the peritumo-
ral injection as indispensable in those tumors located
deeply in the breast (under ultrasound guide if not pal-
pable), associating it to the intradermal injection in su-
perficial ones. Using this combined technique, the
possibility of a misidentification of the SN is reduced. 
It is however necessary to study more women with
tumors not localized in the central area of the breast,
with an informed consent, a double tracer injection
(peritumoral and subareolar) in order to verify the sin-
gleness of the drainage and therefore simplify the SN
identification technique.
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